MS-27-275, an inhibitor of histone deacetylase, has marked in vitro and in vivo antitumor activity against pediatric solid tumors

Jerry Jaboin, Jason Wild, Habib Hamidi, Chand Khanna, Chong Jai Kim, Robert Robey, Susan E. Bates, Carol J. Thiele

Research output: Contribution to journalArticle

183 Citations (Scopus)

Abstract

The antitumor efficacy of the synthetic benzamide derivative MS-27-275 (MS-275), an inhibitor of histone deacetylation [T. Suzuki et al., J. Med. Chem., 42: 3001-3003, 1999], was evaluated in a series of pediatric solid tumor cell lines, including neuroblastoma, rhabdomyosarcoma, Ewing's sarcoma (EWS), retinoblastoma, medulloblastoma, undifferentiated sarcoma (US), osteosarcoma, and malignant rhabdoid tumors. Treatment with MS-275 results in an increase in acetylation of histones within 4 h of drug exposure. The cell lines were treated with various concentrations of MS-275 for 3 days and incubated with [ 3H]thymidine for 20 h before cell harvest. MS-275 inhibited [ 3H]thymidine uptake in a dose-dependent manner in all tumor cell lines examined. The IC 50 ranged from 50 nm in the D283 medulloblastoma cell line to 1.3 μM in the US. A common feature of MS-275 treatment of pediatric tumor cell lines was induction of p21mRNA. However, the effects on cell cycle were diverse because in some cases MS-275 induced an increase in G 1 or G 2, whereas in others, there was an induction of apoptosis. In EWS, the EWS/fli chimeric transcription factor created by the t(11;22) suppresses transforming growth factor (TGF) βRII transcription, however, MS-275 was able to induce an increase in TGF-βRII mRNA and restore TGF-β signaling. Using xenograft orthotopic models of US, EWS, and neuroblastoma, we find that the growth of established tumors is inhibited in mice treated with MS-275.

Original languageEnglish (US)
Pages (from-to)6108-6115
Number of pages8
JournalCancer Research
Volume62
Issue number21
StatePublished - Nov 1 2002
Externally publishedYes

Fingerprint

Histone Deacetylase Inhibitors
Pediatrics
Ewing's Sarcoma
Neoplasms
Transforming Growth Factors
Tumor Cell Line
Sarcoma
Medulloblastoma
Neuroblastoma
Histones
Thymidine
Rhabdoid Tumor
Cell Line
Rhabdomyosarcoma
Retinoblastoma
In Vitro Techniques
entinostat
Osteosarcoma
Acetylation
Heterografts

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Jaboin, J., Wild, J., Hamidi, H., Khanna, C., Kim, C. J., Robey, R., ... Thiele, C. J. (2002). MS-27-275, an inhibitor of histone deacetylase, has marked in vitro and in vivo antitumor activity against pediatric solid tumors. Cancer Research, 62(21), 6108-6115.

MS-27-275, an inhibitor of histone deacetylase, has marked in vitro and in vivo antitumor activity against pediatric solid tumors. / Jaboin, Jerry; Wild, Jason; Hamidi, Habib; Khanna, Chand; Kim, Chong Jai; Robey, Robert; Bates, Susan E.; Thiele, Carol J.

In: Cancer Research, Vol. 62, No. 21, 01.11.2002, p. 6108-6115.

Research output: Contribution to journalArticle

Jaboin, J, Wild, J, Hamidi, H, Khanna, C, Kim, CJ, Robey, R, Bates, SE & Thiele, CJ 2002, 'MS-27-275, an inhibitor of histone deacetylase, has marked in vitro and in vivo antitumor activity against pediatric solid tumors', Cancer Research, vol. 62, no. 21, pp. 6108-6115.
Jaboin, Jerry ; Wild, Jason ; Hamidi, Habib ; Khanna, Chand ; Kim, Chong Jai ; Robey, Robert ; Bates, Susan E. ; Thiele, Carol J. / MS-27-275, an inhibitor of histone deacetylase, has marked in vitro and in vivo antitumor activity against pediatric solid tumors. In: Cancer Research. 2002 ; Vol. 62, No. 21. pp. 6108-6115.
@article{5dcab31957ab4d62ad8bf59f21df6cc4,
title = "MS-27-275, an inhibitor of histone deacetylase, has marked in vitro and in vivo antitumor activity against pediatric solid tumors",
abstract = "The antitumor efficacy of the synthetic benzamide derivative MS-27-275 (MS-275), an inhibitor of histone deacetylation [T. Suzuki et al., J. Med. Chem., 42: 3001-3003, 1999], was evaluated in a series of pediatric solid tumor cell lines, including neuroblastoma, rhabdomyosarcoma, Ewing's sarcoma (EWS), retinoblastoma, medulloblastoma, undifferentiated sarcoma (US), osteosarcoma, and malignant rhabdoid tumors. Treatment with MS-275 results in an increase in acetylation of histones within 4 h of drug exposure. The cell lines were treated with various concentrations of MS-275 for 3 days and incubated with [ 3H]thymidine for 20 h before cell harvest. MS-275 inhibited [ 3H]thymidine uptake in a dose-dependent manner in all tumor cell lines examined. The IC 50 ranged from 50 nm in the D283 medulloblastoma cell line to 1.3 μM in the US. A common feature of MS-275 treatment of pediatric tumor cell lines was induction of p21mRNA. However, the effects on cell cycle were diverse because in some cases MS-275 induced an increase in G 1 or G 2, whereas in others, there was an induction of apoptosis. In EWS, the EWS/fli chimeric transcription factor created by the t(11;22) suppresses transforming growth factor (TGF) βRII transcription, however, MS-275 was able to induce an increase in TGF-βRII mRNA and restore TGF-β signaling. Using xenograft orthotopic models of US, EWS, and neuroblastoma, we find that the growth of established tumors is inhibited in mice treated with MS-275.",
author = "Jerry Jaboin and Jason Wild and Habib Hamidi and Chand Khanna and Kim, {Chong Jai} and Robert Robey and Bates, {Susan E.} and Thiele, {Carol J.}",
year = "2002",
month = "11",
day = "1",
language = "English (US)",
volume = "62",
pages = "6108--6115",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "21",

}

TY - JOUR

T1 - MS-27-275, an inhibitor of histone deacetylase, has marked in vitro and in vivo antitumor activity against pediatric solid tumors

AU - Jaboin, Jerry

AU - Wild, Jason

AU - Hamidi, Habib

AU - Khanna, Chand

AU - Kim, Chong Jai

AU - Robey, Robert

AU - Bates, Susan E.

AU - Thiele, Carol J.

PY - 2002/11/1

Y1 - 2002/11/1

N2 - The antitumor efficacy of the synthetic benzamide derivative MS-27-275 (MS-275), an inhibitor of histone deacetylation [T. Suzuki et al., J. Med. Chem., 42: 3001-3003, 1999], was evaluated in a series of pediatric solid tumor cell lines, including neuroblastoma, rhabdomyosarcoma, Ewing's sarcoma (EWS), retinoblastoma, medulloblastoma, undifferentiated sarcoma (US), osteosarcoma, and malignant rhabdoid tumors. Treatment with MS-275 results in an increase in acetylation of histones within 4 h of drug exposure. The cell lines were treated with various concentrations of MS-275 for 3 days and incubated with [ 3H]thymidine for 20 h before cell harvest. MS-275 inhibited [ 3H]thymidine uptake in a dose-dependent manner in all tumor cell lines examined. The IC 50 ranged from 50 nm in the D283 medulloblastoma cell line to 1.3 μM in the US. A common feature of MS-275 treatment of pediatric tumor cell lines was induction of p21mRNA. However, the effects on cell cycle were diverse because in some cases MS-275 induced an increase in G 1 or G 2, whereas in others, there was an induction of apoptosis. In EWS, the EWS/fli chimeric transcription factor created by the t(11;22) suppresses transforming growth factor (TGF) βRII transcription, however, MS-275 was able to induce an increase in TGF-βRII mRNA and restore TGF-β signaling. Using xenograft orthotopic models of US, EWS, and neuroblastoma, we find that the growth of established tumors is inhibited in mice treated with MS-275.

AB - The antitumor efficacy of the synthetic benzamide derivative MS-27-275 (MS-275), an inhibitor of histone deacetylation [T. Suzuki et al., J. Med. Chem., 42: 3001-3003, 1999], was evaluated in a series of pediatric solid tumor cell lines, including neuroblastoma, rhabdomyosarcoma, Ewing's sarcoma (EWS), retinoblastoma, medulloblastoma, undifferentiated sarcoma (US), osteosarcoma, and malignant rhabdoid tumors. Treatment with MS-275 results in an increase in acetylation of histones within 4 h of drug exposure. The cell lines were treated with various concentrations of MS-275 for 3 days and incubated with [ 3H]thymidine for 20 h before cell harvest. MS-275 inhibited [ 3H]thymidine uptake in a dose-dependent manner in all tumor cell lines examined. The IC 50 ranged from 50 nm in the D283 medulloblastoma cell line to 1.3 μM in the US. A common feature of MS-275 treatment of pediatric tumor cell lines was induction of p21mRNA. However, the effects on cell cycle were diverse because in some cases MS-275 induced an increase in G 1 or G 2, whereas in others, there was an induction of apoptosis. In EWS, the EWS/fli chimeric transcription factor created by the t(11;22) suppresses transforming growth factor (TGF) βRII transcription, however, MS-275 was able to induce an increase in TGF-βRII mRNA and restore TGF-β signaling. Using xenograft orthotopic models of US, EWS, and neuroblastoma, we find that the growth of established tumors is inhibited in mice treated with MS-275.

UR - http://www.scopus.com/inward/record.url?scp=0036828101&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036828101&partnerID=8YFLogxK

M3 - Article

VL - 62

SP - 6108

EP - 6115

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 21

ER -